Breast mesh.
Internal bra complication litigation.
Pre-MDL litigation against Becton Dickinson, Integra LifeSciences, Allergan, and other manufacturers of surgical mesh products used off-label in breast reconstruction, augmentation, and revision procedures — alleging that no breast mesh product holds FDA approval for breast surgery, and that the manufacturers marketed off-label uses without adequate warning.
The plaintiff theory.
The product. The off-label use.
The breast mesh litigation involves claims against manufacturers of surgical mesh products including Becton Dickinson (GalaFLEX, GalaFORM, GalaSHAPE, Phasix, AlloMax), Integra LifeSciences (DuraSorb, SurgiMend), Allergan/LifeCell (AlloDerm, Strattice), and Ethicon (FlexHD). Plaintiffs allege that these mesh products were marketed for off-label use in breast reconstruction, augmentation, and "internal bra" lift procedures, despite never having received FDA approval for breast applications.
The core legal theory rests on the gap between regulatory clearance and clinical use. These products entered the market through the FDA's 510(k) clearance process for general soft-tissue repair — primarily hernia and other applications. Plaintiffs allege that manufacturers actively promoted off-label adoption in breast surgery to grow market share, while failing to warn patients or surgeons about elevated complication rates: infection, mesh erosion, capsular contracture, chronic pain, reconstructive failure, and the need for revision surgery.
The November 2023 FDA letter is the regulatory inflection point of the litigation. The letter explicitly stated that "the safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA," and required Becton Dickinson to update product labeling to reflect that breast use was off-label. Plaintiffs argue the warning came years too late for women who had already received the implants without disclosure of these risks.
Procedural posture.
No MDL yet. Active firm investigation.
No federal multi-district litigation has been formed for breast mesh cases as of early 2026. The litigation is in active firm investigation phase, with attorneys nationwide reviewing potential claims and individual lawsuits being filed in state and federal courts. The pattern broadly resembles the early stages of the prior transvaginal mesh and hernia mesh litigations — both of which produced significant MDLs and substantial settlements after similar pre-MDL investigation periods.
The litigation has structural parallels to the previous mesh waves: the same mesh polymer chemistries (P4HB, polypropylene, biologic acellular dermal matrix), the same defendant set (BD, formerly C.R. Bard), and the same off-label-marketing legal theory. The 2023 FDA action created a procedural foundation for warning-defect claims that did not previously exist in the same form. New filings are accelerating; consolidation is increasingly likely.
Acquisition. Screening.
Retention.
Breast mesh intake requires careful eligibility screening on procedure history (the specific mesh product used, date of surgery, type of breast procedure), complication documentation (infection, revision surgery, mesh removal, chronic pain), and product identification — which is one of the operational chokepoints in this docket. Many patients do not know which mesh product was used in their surgery; identification often requires operative-report retrieval from the surgical facility. We have built docket-specific intake protocols and trained specialists for the targeted medical-record retrieval this litigation requires.
Acquisition runs across paid social, paid search, and connected TV, with creative built specifically for this docket and compliance review on every iteration. Every claimant flows through our multi-vendor fraud-detection suite — Anura, CHEQ, ActiveProspect, TrustedForm, Blacklist Alliance, and Plaid — before reaching the partner firm. Retained cases land directly in the firm's case management system in real time.
For partner firms holding breast mesh dockets, we provide standing operational reporting on retained cases delivered, cost per qualified retention, and case-tier mix against your screening criteria. Strategy sessions cover docket-portfolio decisions: how to position venue selection in the absence of an MDL, which manufacturer-and-product combinations are best positioned if consolidation occurs, and how the prior transvaginal mesh and hernia mesh outcomes inform settlement value expectations on the breast mesh docket.
Start a conversation.
Speak with our team.
A LeadClient case-acquisition strategist will reach out to talk through your docket.